DocGo Announces First Quarter 2026 Results
NEW YORK--( BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the first quarter ended March 31, 2026.
We continued to experience strong volumes across all key business verticals, and especially in our virtual care provider, SteadyMD.
First Quarter 2026 Financial Highlights
Select Corporate Highlights for the First Quarter of 2026 and Recent Weeks
Financial Guidance
Lee Bienstock, Chief Executive Officer of DocGo, commented, “We continued to experience strong volumes across all key business verticals, and especially in our virtual care provider, SteadyMD. We now expect in excess of 50% top-line growth this year at SteadyMD compared to 2025, and even greater growth in our mobile phlebotomy business. As a result of this strength, we are increasing our consolidated 2026 revenue guidance midpoint by $7.5 million dollars.” Bienstock added, “Our strategic alternatives process is also ongoing, and we look forward to providing further updates when prudent.”
Norm Rosenberg, Chief Financial Officer of DocGo, commented “While we are very pleased with the momentum in our top line, this accelerated growth has created some margin inefficiency over the immediate term. This is largely due to an increased pace of hiring, and the use of incentives with our current mobile health workforce to bridge gaps as new full-time hires enter the field. We are also experiencing a meaningful negative impact from the increase in fuel prices caused by the war in the Middle East. We view both factors as temporary and continue to expect favorable margin trends to resume as these forces abate and recent cost cutting and efficiency initiatives flow through in their entirety.” Rosenberg continued, “Subsequent to quarter end, we made progress on collections of the final remaining migrant-related receivables. We believe that we have sufficient liquidity to support our growth initiatives, and our goal remains to achieve adjusted EBITDA profitability in the back half of the year.”
Michael Burdiek, current Chair of DocGo’s audit committee and incoming Chair of the Board, added "As incoming Chair of the Board, the Board of Directors and I look forward to working with management and the recently formed operational review subcommittee to identify additional operational and cost efficiencies that accelerate the Company's pathway to profitability, growth and financial flexibility."
Conference Call and Webcast Details
Monday, May 11 th, 2026, at 5:00 PM ET
1-800-717-1738 - Investors Dial
1-646-307-1865 - Int’l Investors Dial
Conference ID: 15300
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1760676&tp_key=d2cf48e722
The webcast can also be accessed under Events on the Investors section of the Company’s website, https://ir.docgo.com/.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring, ambulance services and a 50-state virtual care network. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote advanced practice provider, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.
Forward-Looking Statements
This earnings release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including the Company’s expectations around projected revenues and adjusted EBITDA for fiscal year 2026; the performance and growth of SteadyMD and the Company’s mobile phlebotomy business and other core business lines; the launch of new Mobile Health programs; the demand for and expansion of the Company’s services; cash flow and cash collections; the Company’s cash balances; margin improvements; and the Company’s achievement of profitability. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking, including, but not limited, to statements regarding the Company’s future actions, business strategies or models, plans, goals, future events, future revenues, future margins, current and future revenue guidance, future growth or performance, financing needs, business trends, results of operations, objectives and intentions with respect to future operations, services and products, and new and existing contracts or partnerships. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions.
Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause its actual results or outcomes, or the timing of its results or outcomes, to differ materially from those contained in its forward-looking statements, including, but not limited to the following: impacts related to the wind down of migrant-related services; the Company’s ability to continue as a going concern; the Company’s ability to maintain its listing on Nasdaq; the Company’s ability to pursue strategic initiatives to deliver on shareholder value; the Company’s ability to expand its programs with insurance partners, hospital systems, municipalities and other strategic partners; the Company’s ability to successfully implement its business strategy, including delivering value to shareholders via buybacks and funding new strategic relationships; the Company’s ability to establish, maintain and grow customer relationships; the Company’s ability to execute projects to the satisfaction of its customers; the Company’s ability to grow demand for its care gap closure programs and other services; the Company’s ability to maintain or grow its cash balances; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and other strategic partners; the Company’s ability to compete effectively in a highly competitive industry, including conditions in the healthcare transportation and mobile health services markets; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts, including changes in government spending on healthcare and other social services; recent revenue growth derived from a small number of large customers; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s M&A activity and success of its acquisition strategy; the Company’s ability to retain its workforce and management personnel and successfully manage leadership transitions; the availability of healthcare professionals and other personnel; changes in the cost of labor; the Company’s ability to collect on customer receivables; risks associated with the Company’s share repurchase program; overall macroeconomic and geopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the ongoing or any future shutdown of the U.S. federal government; the ability of the Company’s suppliers to meet its needs; the Company’s ability to obtain or maintain operating licenses; potential changes in federal, state or local government policies or priorities; expected impacts of geopolitical instability; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; the Company’s ability to improve gross margins; the Company’s ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives; legislative and regulatory actions; the impact of legal proceedings and compliance risk; volatility of our stock price; the impact on the Company’s business and reputation in the event of information technology system failures, network disruptions, cyber incidents or losses or unauthorized access to, or release of, confidential information; the Company’s ability to comply with laws and regulations regarding data privacy and protection and other risk factors included in the Company’s filings with the Securities and Exchange Commission (“SEC”).
Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this earnings release. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results or outcomes could differ materially from those described in the forward-looking statements.
The forward-looking statements made in this earnings release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this earnings release to reflect events or circumstances after the date of this earnings release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law. The Company’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.
$
35,675,081
$
51,018,657
93,965,449
92,893,216
5,276,630
4,790,215
3,248,628
3,697,371
138,165,788
152,399,459
13,637,905
14,558,427
644,134
—
11,140,255
1,466,121
13,119,276
15,845,875
10,248,516
11,520,781
18,120,270
17,420,424
814,032
538,864
3,336,687
3,353,061
$
209,226,863
$
217,103,012
$
13,866,403
$
11,110,867
44,728,154
42,789,440
49,278
51,740
338,360
336,982
8,100,376
3,040,377
4,288,907
4,650,953
5,845,230
5,509,687
77,216,708
67,490,046
171,714
183,843
2,476,216
4,776,215
6,610,293
7,563,664
11,541,541
11,217,907
98,016,472
91,231,675
9,878
9,864
328,618,933
325,416,366
(198,564,926
)
(183,801,795
)
2,247,984
2,387,404
132,311,869
144,011,839
(21,101,478
)
(18,140,502
)
111,210,391
125,871,337
$
209,226,863
$
217,103,012
2026
2025
$
75,550,484
$
96,033,055
51,667,588
65,185,060
30,835,068
32,902,070
2,647,107
3,761,391
5,034,130
4,210,823
3,705,049
3,639,444
372,633
331,705
94,261,575
110,030,493
(18,711,091
)
(13,997,438
)
(99,732
)
(426,284
)
(2,760,000
)
—
4,687,798
—
—
(40,698
)
—
(40,837
)
(62,493
)
15,139
264,964
(312,869
)
2,030,537
(805,549
)
(16,680,554
)
(14,802,987
)
(19,283
)
3,723,687
(16,699,837
)
(11,079,300
)
(1,936,706
)
(1,673,985
)
(14,763,131
)
(9,405,315
)
(71,904
)
—
(67,516
)
495,538
$
(14,902,551
)
$
(8,909,777
)
$
(0.15
)
$
(0.09
)
98,746,095
101,594,579
$
(0.15
)
$
(0.09
)
98,746,095
101,594,579
2026
2025
$
(16,699,837
)
$
(11,079,300
)
1,266,513
1,220,806
21,038
1,299,142
1,359,556
1,241,443
62,493
(15,139
)
(253,775
)
(3,927,428
)
(78,004
)
—
—
40,698
1,732,911
1,247,991
3,224,784
4,830,312
—
40,837
2,760,000
—
(2,803,766
)
31,437,734
(37,672
)
(386,734
)
16,374
538,190
2,700,501
(8,308,173
)
1,938,714
(9,148,984
)
132,363
185,334
(4,657,807
)
9,216,729
(430,310
)
(1,029,626
)
(665,172
)
(712,711
)
—
(3,646,318
)
(1,731,066
)
—
4,463,765
—
21,903
94,341
1,659,120
(5,294,314
)
(14,551
)
(3,060
)
—
(265,538
)
(1,024,270
)
—
(22,203
)
(1,200,977
)
—
(5,751,954
)
(1,403,655
)
(1,296,887
)
(2,464,679
)
(8,518,416
)
(206,076
)
317,738
(5,669,442
)
(4,278,263
)
52,484,778
107,337,307
$
46,815,336
$
103,059,044
2026
2025
$
47,031
$
561,707
$
248,568
$
220,055
$
15,791
$
1,906,712
$
2,114,291
$
5,966,095
$
55,035
$
438,738
$
35,675,081
$
79,007,535
11,140,255
24,051,509
$
46,815,336
$
103,059,044
Non-GAAP Financial Measures
The following information provides definitions and reconciliation of non-GAAP financial measures used by the Company to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles (“GAAP”). The Company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measures used by the Company may differ from similarly titled measures used by other companies.
Adjusted Gross Margin
Adjusted gross profit and adjusted gross margin are considered non-GAAP financial measures under SEC rules because they exclude certain amounts included in gross profit and gross margin calculated in accordance with GAAP. Adjusted gross profit is total revenue minus cost of revenue, excluding depreciation and amortization (which are shown separately), and adjusted gross margin is adjusted gross profit as a percentage of total revenue.
The Company’s management believes that adjusted gross margin is useful in evaluating DocGo’s operating performance, as the calculation of this measure excludes the impact of non-cash depreciation and amortization charges. The Company’s management believes that by using adjusted gross margin in conjunction with GAAP gross margin, investors will get a more complete view of what management considers to be the Company’s core operating performance and allow for comparison of this measure when compared to those of prior periods. While many companies use adjusted gross margin as a performance measure, not all companies use identical calculations for determining adjusted gross margin. As such, DocGo’s presentation of adjusted gross margin might not be comparable to similarly titled measures of other companies.
Adjusted EBITDA
Adjusted EBITDA is considered a non-GAAP financial measure under SEC rules because it excludes certain amounts included in net income (loss) calculated in accordance with GAAP. Specifically, adjusted EBITDA is arrived at by taking reported GAAP net income and adding back the following items: net interest expense (income), provision for (benefit from) income taxes, depreciation and amortization, other (income) expense, non-cash equity-based compensation and certain other non-recurring expenses consisting of certain one-time legal settlements and certain one-time expenses incurred in connection with acquisitions and other corporate activities, beyond those that are typically incurred.
The Company’s management believes that its adjusted EBITDA measure is useful in evaluating DocGo’s operating performance, as the calculation of this measure generally eliminates the effect of financing and income taxes and the accounting effects of capital spending and acquisitions, as well as other items of a non-recurring and/or non-cash nature. Adjusted EBITDA is not intended to be a measure of GAAP cash flow, as this measure does not consider certain cash-based expenses, such as payments for taxes or debt service.
Management believes that using adjusted EBITDA in conjunction with GAAP measures such as net income assists investors in getting a more complete picture of the Company’s financial results and operations, affording them with a more complete view of what management considers to be the Company’s core operating performance as well as offering the ability to assess such performance as compared with that of prior periods and management’s public guidance. While many companies use adjusted EBITDA as a performance measure, not all companies use identical calculations for determining adjusted EBITDA. As such, DocGo’s presentation of adjusted EBITDA might not be comparable to similarly titled measures of other companies.
Reconciliation of Non-GAAP Measures
The table below reflects the reconciliation of GAAP gross margin and adjusted gross margin for the three months ended March 31, 2026 compared to the same period in 2025:
2026
2025
$
75,550,484
$
96,033,055
(51,667,588
)
(65,185,060
)
(2,647,107
)
(3,761,391
)
21,235,789
27,086,604
2,647,107
3,761,391
$
23,882,896
$
30,847,995
28.1
%
28.2
%
31.6
%
32.1
%
The table below reflects the reconciliation of net income (loss) to adjusted EBITDA for the three months ended March 31, 2026 compared to the same period in 2025 (in millions):
2026
2025
$
(16.7
)
$
(11.1
)
0.1
0.4
-
(3.7
)
2.6
3.8
(2.1
)
0.4
(16.1
)
(10.2
)
3.2
4.8
2.7
1.5
$
(10.2
)
$
(3.9
)
$
75.6
$
96.0
(22.1
)%
(15.4
)%
(22.1
)%
(11.6
)%
(13.5
)%
(4.1
)%
The table below reflects the reconciliation of operating expenses to adjusted operating expenses for the three months ended March 31, 2026 compared to the same period in 2025 and the three months ended December 31, 2025 (in millions):
2026
2025
2025
$
42.6
$
44.8
$
128.9
(2.6
)
(3.8
)
(3.9
)
(3.2
)
(4.8
)
(3.1
)
(2.7
)
(1.5
)
(86.2
)
$
34.1
$
34.7
$
35.7